a in several animal models of angiogenesis and nerve injury.
We also have impressive data from our prior Phase 1 clinical study,
SB-509-401, with a single treatment in the same patient population. In
addition, we have encouraging positive interim data in our SB-509-701A
study in which we are assessing recovery of nerve conduction velocity (NCV)
in subjects with moderate to severe DN after two treatments with SB-509.
Recovery of NCV in this more severe population that presents with "blocked"
nerves or nerves with unmeasurable NCVs provides a binary outcome. The
SB-509-701A trial is nearly complete and we expect to have more data from
this study in the first quarter of 2009."
"The results from the SB-509-601 study are certainly unexpected,"
stated Edward Lanphier, Sangamo's president and CEO. "The data that we
obtained on measures of nerve health and function are quite different than
what we observed in our Phase 1b study. However, the 601 trial is only one
part of our broad clinical development program to evaluate SB-509 which we
will continue to prosecute. Based on our positive Phase 1b clinical data
and encouraging interim data from our Phase 2 repeat-dosing study
(SB-509-701A) in subjects with moderate to severe DN, we continue to have a
high degree of confidence in this drug."
Conference Call
Sangamo will host a conference call today, November 10, 2008 at 5:00
p.m. ET, which will be open to the public. The call will also be webcast
live and can be accessed via a link on the Sangamo BioSciences website in
the Investor Relations section under "Events and Presentations"
http://investor.sangamo.com/events.cfm . The webcast replay will also be
available for two weeks after the call. During the conference call, the
company will review the data presented today.
The conference call dial-in numbers are 888-690-2875 for domestic
callers and 913-981-5543 for international callers.
'/>"/>
SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Sangamo BioSciences Reports Third Quarter 2008 Financial Results2.
Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic3.
Sangamo BioSciences Announces Third Quarter Conference Call and Webcast4.
Sangamo BioSciences to Present at Two Upcoming Investor Conferences5.
Sangamo BioSciences to Present at the UBS Global Life Sciences Conference6.
Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference7.
Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference8.
Sangamo BioSciences Reports Second Quarter 2008 Financial Results9.
Sangamo BioSciences Announces Second Quarter Conference Call and Webcast10.
Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals11.
Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants